Innocent Information

Creative Biolabs Provides Customized Payload Services for Antibody-drug Conjugate

 Breaking News
  • No posts were found

Creative Biolabs Provides Customized Payload Services for Antibody-drug Conjugate

August 26
13:06 2019

New York, US – August 26, 2019 – Creative Biolabs, an expert in antibody-drug conjugates development, is committed to helping clients design and prepare highly customized payload based on an its extensive library and the proprietary “DrugLnk” platform.

Antibody-drug conjugate has emerged as a novel immunotherapy for a wide range of disease over these years, of which the payload interacts with intracellular targets and blocks crucial cellular metabolic pathways, eventually leading to cell death. 

As a fundamental component of ADCs, a suitable ADC payload requires extremely high cytotoxic efficacy to compensate the low drug concentration, a relatively small size to minimize the risk of immunogenicity, an adequate plasma stability to maintain drug efficacy. With a deep understanding of these strict standards, Creative Biolabs is capable of preparing various customized payload services, including but not limited to microtubule toxins, DNA toxins, transcription toxins, inhibitors, and other payloads.

Composed of heterodimers that comprise of two tubulin isoforms, microtubules play dynamic role in chromosomal movement during mitosis, intracellular transportation, organelle motion and organization, featured by intrinsic instability, for instance, the haploid microtubules. Up to now, microtubule toxin based ADCs from Creative Biolabs have been used in clinical treatment considering the potential side effects, especially toxic moieties, including auristatins, epothilone, maytansinoids, taxoids, tubulysins, and vinorelbine. Researchers at Creative Biolabs specialized in antibody-drug conjugates field have made years of efforts to study a highly efficient conjugation method to avoid toxicity to normal tissues and thus enhance drug concentration in target cancer tissue.

As for transcription toxins, the complexity of gene transcription makes numerous potential drug targets possible. Transcription inhibitions uitilize the distinct sensitivity between normal and tumor cells and result in a reversible growth arrest and an efficient induction of apoptosis. Creative Biolabs provides transcription toxins such as amatoxins (targeting RNA polymerase II) and thailanstatin A (targeting spliceosome) as ADC payloads. Amatoxins, especially α-amanitin, featured by specific MOA and high water solubility are mainly two popular ADC payloads at Creative Biolabs while Thailanstatin A is another one, modified with the installation of a N-hydroxysuccinimide (NHS) ester and successfully conjugated to Trastuzumab via amine-based lysine conjugation to generate a virtually “linkerless” ADC. 

In addition, relying on the professional “DrugLnk” platform, Creative Biolabs also can help clients to:

  • Design linkers with optimal size
  • Select linkers with suitable release mechanism
  • Engineer linkers with compatible conjugation chemistry
  • Synthesize customized linkers
  • Modify payload drug
  • Design synthesis routes
  • Synthesize customized drug-linker complexes

More information on antibody-drug conjugates can be reached at https://www.creative-biolabs.com/adc/

About Creative Biolabs

With more than a decade of exploration and expansion, Creative Biolabs provides current research and service capacity that covers the entire new drug discovery and development pipeline, ranging from early discovery, pre-clinical evaluations, cGMP manufacturing, to clinical trials. As an international cooperation, Creative Biolabs established offices all around the globe with more than 200 well-trained full-time scientists and technicians, who work closely with customers and research partners to develop new medicines for a better, healthier world. After years of pursuit for perfection, Creative Biolabs has established leadership in targeted immunotherapy and antibody-drug conjugate (ADC) development. They offer customers comprehensive one-stop-shop of all aspects in ADC research and evaluation, ranging from antigen selection, antibody production/optimization, payload-linker synthesis, ADC conjugation, to various stages of ADC characterization and pre-clinical evaluation.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-619-7922
Address:45-1 Ramsey Road
City: Shirley
State: New York
Country: United States
Website: https://www.creative-biolabs.com/adc/